vs
嘉德诺（BTSG）与LG化学（CHE）财务数据对比。点击上方公司名可切换其他公司
嘉德诺的季度营收约是LG化学的8.5倍（$3.6B vs $420.0M）。LG化学净利率更高（15.8% vs 2.2%，领先13.6%）。嘉德诺同比增速更快（16.3% vs 3.1%）。过去两年嘉德诺的营收复合增速更高（17.4% vs 5.9%）
嘉德诺是美国跨国医疗服务企业，位列美国企业营收榜第15位，总部位于俄亥俄州都柏林。公司主营药品与医疗产品分销，服务覆盖超10万个网点，同时生产手套、手术服、流体管理产品等医用外科用品，还运营着规模位居前列的放射性药物网络。
LG化学是韩国最大的化工企业，总部位于韩国首尔，2021年按销售额统计为全球第九大化工企业。其前身为生产化妆品的乐喜化学工业株式会社，目前已全面转型为仅面向企业客户的B2B经营模式。
BTSG vs CHE — 直观对比
营收规模更大
BTSG
是对方的8.5倍
$420.0M
营收增速更快
BTSG
高出13.2%
3.1%
净利率更高
CHE
高出13.6%
2.2%
两年增速更快
BTSG
近两年复合增速
5.9%
损益表 — Q4 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $3.6B | $420.0M |
| 净利润 | $77.1M | $66.3M |
| 毛利率 | 11.6% | — |
| 营业利润率 | 3.0% | 20.1% |
| 净利率 | 2.2% | 15.8% |
| 营收同比 | 16.3% | 3.1% |
| 净利润同比 | 381.8% | -7.6% |
| 每股收益（稀释后） | $0.34 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BTSGCHE
| Q1 26 | — | $420.0M | ||
| Q4 25 | $3.6B | $639.3M | ||
| Q3 25 | $3.3B | $624.9M | ||
| Q2 25 | $3.1B | $618.8M | ||
| Q1 25 | $2.9B | $646.9M | ||
| Q4 24 | $3.1B | $411.0M | ||
| Q3 24 | $2.9B | $391.4M | ||
| Q2 24 | $2.7B | $374.6M |
净利润BTSGCHE
| Q1 26 | — | $66.3M | ||
| Q4 25 | $77.1M | $76.8M | ||
| Q3 25 | $55.8M | $64.2M | ||
| Q2 25 | $28.2M | $52.5M | ||
| Q1 25 | $29.5M | $71.8M | ||
| Q4 24 | $16.0M | $90.3M | ||
| Q3 24 | $-8.2M | $75.8M | ||
| Q2 24 | $19.9M | $70.9M |
毛利率BTSGCHE
| Q1 26 | — | — | ||
| Q4 25 | 11.6% | 35.2% | ||
| Q3 25 | 11.8% | 31.5% | ||
| Q2 25 | 11.9% | 29.8% | ||
| Q1 25 | 11.8% | 33.5% | ||
| Q4 24 | 13.8% | 1.2% | ||
| Q3 24 | 14.0% | -1.2% | ||
| Q2 24 | 14.2% | -4.1% |
营业利润率BTSGCHE
| Q1 26 | — | 20.1% | ||
| Q4 25 | 3.0% | 15.7% | ||
| Q3 25 | 2.6% | 12.0% | ||
| Q2 25 | 1.5% | 11.0% | ||
| Q1 25 | 1.8% | 14.6% | ||
| Q4 24 | 2.6% | 27.7% | ||
| Q3 24 | 2.0% | 23.5% | ||
| Q2 24 | 2.3% | 23.5% |
净利率BTSGCHE
| Q1 26 | — | 15.8% | ||
| Q4 25 | 2.2% | 12.0% | ||
| Q3 25 | 1.7% | 10.3% | ||
| Q2 25 | 0.9% | 8.5% | ||
| Q1 25 | 1.0% | 11.1% | ||
| Q4 24 | 0.5% | 22.0% | ||
| Q3 24 | -0.3% | 19.4% | ||
| Q2 24 | 0.7% | 18.9% |
每股收益（稀释后）BTSGCHE
| Q1 26 | — | — | ||
| Q4 25 | $0.34 | $5.45 | ||
| Q3 25 | $0.26 | $4.46 | ||
| Q2 25 | $0.13 | $3.57 | ||
| Q1 25 | $0.14 | $4.86 | ||
| Q4 24 | $0.11 | $6.00 | ||
| Q3 24 | $-0.04 | $5.00 | ||
| Q2 24 | $0.10 | $4.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $88.4M | $16.9M |
| 总债务越低越好 | $2.5B | $91.2M |
| 股东权益账面价值 | $1.9B | $848.0M |
| 总资产 | $6.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 1.34× | 0.11× |
8季度趋势，按日历期对齐
现金及短期投资BTSGCHE
| Q1 26 | — | $16.9M | ||
| Q4 25 | $88.4M | $74.5M | ||
| Q3 25 | $140.3M | $129.8M | ||
| Q2 25 | $70.1M | $249.9M | ||
| Q1 25 | $52.3M | $173.9M | ||
| Q4 24 | $61.3M | $178.3M | ||
| Q3 24 | $36.0M | $238.5M | ||
| Q2 24 | $25.0M | $222.9M |
总债务BTSGCHE
| Q1 26 | — | $91.2M | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.6B | — |
股东权益BTSGCHE
| Q1 26 | — | $848.0M | ||
| Q4 25 | $1.9B | $979.4M | ||
| Q3 25 | $1.8B | $1.1B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.7B | $1.2B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | $1.6B | $1.2B |
总资产BTSGCHE
| Q1 26 | — | $1.5B | ||
| Q4 25 | $6.4B | $1.5B | ||
| Q3 25 | $6.0B | $1.6B | ||
| Q2 25 | $5.9B | $1.7B | ||
| Q1 25 | $5.8B | $1.7B | ||
| Q4 24 | $5.9B | $1.7B | ||
| Q3 24 | $5.8B | $1.8B | ||
| Q2 24 | $5.6B | $1.7B |
负债/权益比BTSGCHE
| Q1 26 | — | 0.11× | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.38× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.58× | — | ||
| Q3 24 | 1.65× | — | ||
| Q2 24 | 1.63× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $231.6M | $88.2M |
| 自由现金流经营现金流 - 资本支出 | $193.9M | — |
| 自由现金流率自由现金流/营收 | 5.5% | — |
| 资本支出强度资本支出/营收 | 1.1% | 4.1% |
| 现金转化率经营现金流/净利润 | 3.00× | 1.33× |
| 过去12个月自由现金流最近4个季度 | $394.7M | — |
8季度趋势，按日历期对齐
经营现金流BTSGCHE
| Q1 26 | — | $88.2M | ||
| Q4 25 | $231.6M | $133.5M | ||
| Q3 25 | $107.9M | $83.4M | ||
| Q2 25 | $49.1M | $138.6M | ||
| Q1 25 | $101.6M | $32.7M | ||
| Q4 24 | $90.6M | $164.9M | ||
| Q3 24 | $27.2M | $90.5M | ||
| Q2 24 | $-15.2M | $77.5M |
自由现金流BTSGCHE
| Q1 26 | — | — | ||
| Q4 25 | $193.9M | $117.2M | ||
| Q3 25 | $92.2M | $66.0M | ||
| Q2 25 | $24.7M | $122.8M | ||
| Q1 25 | $84.0M | $19.5M | ||
| Q4 24 | $75.3M | $152.2M | ||
| Q3 24 | $7.2M | $77.0M | ||
| Q2 24 | $-39.0M | $66.5M |
自由现金流率BTSGCHE
| Q1 26 | — | — | ||
| Q4 25 | 5.5% | 18.3% | ||
| Q3 25 | 2.8% | 10.6% | ||
| Q2 25 | 0.8% | 19.8% | ||
| Q1 25 | 2.9% | 3.0% | ||
| Q4 24 | 2.5% | 37.0% | ||
| Q3 24 | 0.2% | 19.7% | ||
| Q2 24 | -1.4% | 17.7% |
资本支出强度BTSGCHE
| Q1 26 | — | 4.1% | ||
| Q4 25 | 1.1% | 2.6% | ||
| Q3 25 | 0.5% | 2.8% | ||
| Q2 25 | 0.8% | 2.6% | ||
| Q1 25 | 0.6% | 2.1% | ||
| Q4 24 | 0.5% | 3.1% | ||
| Q3 24 | 0.7% | 3.5% | ||
| Q2 24 | 0.9% | 3.0% |
现金转化率BTSGCHE
| Q1 26 | — | 1.33× | ||
| Q4 25 | 3.00× | 1.74× | ||
| Q3 25 | 1.93× | 1.30× | ||
| Q2 25 | 1.74× | 2.64× | ||
| Q1 25 | 3.44× | 0.46× | ||
| Q4 24 | 5.66× | 1.83× | ||
| Q3 24 | — | 1.19× | ||
| Q2 24 | -0.76× | 1.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BTSG
| Medicare D | $1.1B | 32% |
| Commercial Insurance | $879.8M | 25% |
| Medicare C | $641.2M | 18% |
| Provider Services | $394.2M | 11% |
| Medicaid | $301.4M | 8% |
| Medicare A | $150.5M | 4% |
| Private And Other | $44.0M | 1% |
| Medicare B | $19.5M | 1% |
| Pharmacy Solutions And Provider Services Segments | $19.0M | 1% |
CHE
| Homecare | $371.1M | 88% |
| Inpatient | $35.9M | 9% |
| Other | $13.0M | 3% |
